An internal standard for the quantification of fluvastatin
Related Products
Unlabeled Version(s)
10010334Fluvastatin
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Fluvastatin-d6 (sodium salt)

Item No. 25433

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(3R,5S,E)-7-(3-(4-fluorophenyl)-1-(propan-2-yl-1,1,1,3,3,3-d6)-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoate, monosodium salt
Molecular Formula
C24H19D6FNO4 • Na
Formula Weight
439.5
Purity
≥95% (mixture of enantiomers)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
Methanol: Slightly solubleWater: Slightly soluble
SMILES
FC1=CC=C(C=C1)C2=C(/C=C/[C@@H](O)C[C@@H](O)CC([O-])=O)N(C(C([2H])([2H])[2H])C([2H])([2H])[2H])C3=C2C=CC=C3.[Na+]
InChi Code
InChI=1S/C24H26FNO4.Na/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);/q;+1/p-1/b12-11+;/t18-,19-;/m1./s1/i1D3,2D3;
InChi Key
ZGGHKIMDNBDHJB-VOEOVFABSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $523

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Fluvastatin-d6 is intended for use as an internal standard for the quantification of fluvastatin (Item Nos. 10010334 | 10010337) by GC- or LC-MS. Fluvastatin is an inhibitor of HMG-CoA reductase (Ki = 0.3 nM for the rat enzyme).1,2 It also inhibits the human cytochrome P450 (CYP) isoform CYP2C9 (IC50 = 100 nM).3 Fluvastatin inhibits oxidized LDL-induced ferroptosis and reverses oxidized LDL-induced decreases in glutathione peroxidase 4 (GPX4) and system Xc- cystine-glutamate antiporter levels in human umbilical vein endothelial cells (HUVECs).4 In vivo, fluvastatin (2 mg/kg per day) decreases serum cholesterol, triglyceride, and phospholipid levels, the formation of thiobarbituric acid-reactive substances (TBARS), and vascular angiotensin-converting enzyme (ACE) activity in rabbits fed a high-cholesterol diet.5 It increases survival in a mouse model of myocardial infarction when administered at a dose of 10 mg/kg per day.6 Formulations containing fluvastatin have been used in the treatment of hypercholesterolemia and the prevention of cardiovascular disease.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Istvan, E.S., and Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292(5519), 1160-1164 (2001).

    2. Corsini, A., Maggi, F.M., and Catapano, A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res. 31(1), 9-27 (1995).

    3. Transon, C., Leemann, T., and Dayer, P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 50(3), 209-215 (1996).

    4. Li, Q., Liu, C., Deng, L., et al. Novel function of fluvastatin in attenuating oxidized low-density lipoprotein-induced endothelial cell ferroptosis in a glutathione peroxidase4- and cystine-glutamate antiporter-dependent manner. Exp. Ther. Med. 22(5), 1275 (2021).

    5. Mitani, H., Bandoh, T., Ishikawa, J., et al. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br. J. Pharmacol. 119(6), 1269-1275 (1996).

    6. Hayashidani, S., Tsutsui, H., Shiomi, T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105(7), 868-873 (2002).